Zhejiang Int'l Medicine Co., Ltd. Sustainability Profile
Zhejiang Int'l Medicine Co., Ltd., commonly referred to as Zhejiang Medicine, is a prominent player in the pharmaceutical industry, headquartered in China. Established in 1995, the company has made significant strides in the development and distribution of high-quality medicinal products, primarily focusing on APIs (Active Pharmaceutical Ingredients) and finished dosage forms. With a strong operational presence across Asia and expanding into international markets, Zhejiang Medicine is renowned for its commitment to innovation and quality. The company’s core offerings include a diverse range of generic drugs and specialty pharmaceuticals, distinguished by their adherence to stringent regulatory standards. Recognised for its robust market position, Zhejiang Int'l Medicine has achieved notable milestones, including certifications from global health authorities, which underscore its dedication to excellence in healthcare solutions.
DitchCarbon Score
How does Zhejiang Int'l Medicine Co., Ltd.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Zhejiang Int'l Medicine Co., Ltd.'s score of 22 is lower than 78% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Zhejiang Int'l Medicine Co., Ltd.'s reported carbon emissions
Zhejiang Int'l Medicine Co., Ltd., headquartered in China, currently does not report specific carbon emissions data, as indicated by the absence of emissions figures. The company is a current subsidiary of Zhejiang Int'l Group Co., Ltd., which may influence its climate commitments and reporting practices. While there are no documented reduction targets or climate pledges from Zhejiang Int'l Medicine Co., Ltd., it is important to note that emissions data may be inherited from its parent company, Zhejiang Int'l Group Co., Ltd. This relationship could potentially provide insights into broader corporate sustainability initiatives and emissions management strategies. As of now, the company has not established specific science-based targets (SBTi) or other industry-standard reduction initiatives. The lack of reported emissions data and reduction commitments highlights a potential area for improvement in transparency and accountability regarding climate impact.
How Carbon Intensive is Zhejiang Int'l Medicine Co., Ltd.'s Industry?
How Carbon Intensive is Zhejiang Int'l Medicine Co., Ltd.'s Location?
Zhejiang Int'l Medicine Co., Ltd.'s Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Zhejiang Int'l Medicine Co., Ltd. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
